Amnestic Mild Cognitive Impairment (aMCI) is now commonly accepted to reflect a prodrome of Alzheimer disease. This has led to a greater focus on employing measures in clinical settings that are more sensitive to the presence of MCI. While delayed recall and rate of forgetting had been previously considered the hallmark of medial temporal lobe dysfunction in AD, it has become increasingly recognized that deficits in measures of initial learning may be as sensitive, as or more sensitive than delayed recall in the identification of MCI. It was found that melatonin does not reverse the dementia symptoms in the final phases of Alzheimer disease but there was improvement in sleep-wake abnormalities, circadian rhythm disturbances, and sundown syndrome in these patients. Melatonin therapy was also seen to improve sleep quality, cognitive performance, memory, and depression in patients with mild cognitive impairment.
Top journals serve as an important forum for researchers and academicians from where they can access important information about recent developments in their field. These journals are the first choice for any in-depth examination of an issue related to science. Science as we know is scarcely imaginable without the academic journal.
Last date updated on July, 2014